



Comparison of Major PCSK9 Inhibitor Trials: FOURIER and ODYSSEY OUTCOMES

Study	FOURIER (evolocumab) ¹	ODYSSEY OUTCOMES (alirocumab) ²
Primary endpoint (composite)	cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization	coronary heart disease death, non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, or hospitalization for unstable angina
Treatment versus placebo	9.8% versus 11.3%	9.5% versus 11.1%
Median follow up	2.2 years	2.8 years
Hazard ratio	0.85	0.85
Number needed to treat	67	64

Adapted by Wesley Milks, MD, The Ohio State University

1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664.

2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563-e595. doi:10.1161/CIR.000000000000067.